The Spanish biopharmaceutical company PharmaMar announced that its business partner in South Korea, Boryung Pharmaceutical, presented a drug with great antiviral potency against the new coronavirus, which demonstrates 80 times greater antiviral efficacy than remdesivir, one of the main drugs for treating Covid-19.
This is the drug plitidepsin, known commercially as Aplidin, to treat multiple myeloma (a type of plasma cell cancer) in Australia. “Its safety profile in humans was confirmed in hundreds of patients in various clinical trials in Europe and the US,” they said in a statement.
“With these data of such powerful antiviral activity, it is expected to reduce the progression of the disease to Acute Respiratory Distress Syndrome (ARDS) in hospitalized patients with COVID-19 pneumonia, together with a rapid improvement in symptoms,” he points out. .
They hope that with this medication they can reduce the “progression of the disease to Acute Respiratory Distress Syndrome (ARDS) in hospitalized patients with pneumonia due to Covid-19”.
Boryung Pharmaceutica is preparing clinical trials with plitidepsin in South Korea, which will take place in the third quarter of this year. On the other hand, its use has already been confirmed in hundreds of patients in various clinical trials in Europe and the United States.
—
